Security readout for executives and security teams
Plain-English summary
CVE-2023-38958 affects ZKTeco BioAccess IVS v3.3.1, a physical access control platform. The reported issue could let an unauthenticated remote attacker open or close doors managed by the platform using a crafted web request.
Executive priority
Treat this as high priority if BioAccess IVS v3.3.1 is deployed, because the impact crosses from IT into physical site access. Prioritize exposure reduction while awaiting verified vendor guidance.
Technical view
The source describes an access control flaw in BioAccess IVS v3.3.1. The vulnerable behavior is remote door operation without authentication via crafted web requests. No CVSS score, CWE, fixed version, or detailed vendor remediation is provided in the supplied sources.
Likely exposure
Organizations using ZKTeco BioAccess IVS v3.3.1 are the known exposure group, especially where the web interface is reachable from untrusted networks or broad internal segments.
Exploitation context
The bundle does not show CISA KEV listing or active exploitation evidence. Public detail confirms a crafted web request vector, but does not provide exploit maturity, prevalence, or observed attacks.
Researcher notes
Evidence is limited to the CVE description and Claroty reference. The affected version is specifically v3.3.1. Do not assume broader ZKTeco product impact, exploit availability, or a fixed version from the supplied data.
Mitigation direction
- Identify any ZKTeco BioAccess IVS v3.3.1 deployments.
- Restrict BioAccess IVS web access to trusted admin networks or VPN.
- Check ZKTeco and Claroty guidance for fixes or compensating controls.
- Review door-operation logs for unexpected remote open or close events.
- Increase monitoring around physical access control management systems.
Validation and detection
- Confirm deployed BioAccess IVS versions and management interface locations.
- Map network reachability to the BioAccess IVS web interface.
- Verify authentication is required for all door-control workflows.
- Review audit logs for unexplained door state changes.
- Document vendor remediation status before accepting residual risk.
Public sources used
Generated from the cited source records. This long-tail analysis has not been individually reviewed by a named human.
Conservative CVE-to-ATT&CK context
These mappings and lookup hints may be relevant to the vulnerability behavior, CWE, affected product, or exposure path. Glexia-inferred context is not an official MITRE, ATT&CK, CWE, or CVE Program mapping.
ATT&CK lookup starting points
Use these exact CWE pages and searches to review the Glexia ATT&CK library from this CVE's weakness and description context.
CVE-2023-38958 mapping review
Open the CVE-to-ATT&CK bridge for reviewed, inferred, or future official mappings tied to this CVE.
Open ATT&CK lookup- Severity
- Unknown
- CVSS
- Not scored
- Known Exploited
- No
- Published
CNA and ADP enrichment extracted from CVE v5
These fields come from the CVE record and ADP containers, not from Glexia's Take. They preserve time-varying source decisions such as CISA SSVC, KEV status, CVSS metrics, and provider references.
SSVC decision data
Vulnerability timeline
Timeline events are normalized from CVE metadata, CNA source timelines, ADP timelines, and KEV metadata when present.
- CVE reservedCVE Program
The CVE ID was reserved by the assigning CNA.
- CVE publishedCVE Program
The CVE record was published.
- CVE updatedCVE Program
The CVE record metadata indicates this as the latest update time.
ADP provider summaries
Source materials
- CVE List V5 sourceCVE List V5
- https://claroty.com/team82/disclosure-dashboard/cve-2023-38958CVE reference, mitre
Products and packages named in the record
CWE details
CWE links open Glexia weakness intelligence pages with official CWE context, developer remediation guidance, and related CVE mappings.